Reports
Sale
Global Sickle Cell Disease Treatment Market Size, Forecast: By Treatment Type: Medications, Blood Transfusion, Bone Marrow Transplant, Others; By Diseases Type; By Population Type; By Dosage Form; By Drug Type; By End User; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Sickle Cell Disease Treatment Market Outlook
The global sickle cell disease treatment market size was valued at USD 5.38 billion in 2023, driven by rising accessibility to resources and treatment facilities, growing awareness about sickle cell disease treatment, and increasing demand for blood transfusion treatment. The market is forecasted to grow at a CAGR of 16.9% during the forecast period of 2024-2032 to achieve a value of USD 21.92 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increased Demand for Blood Transfusion Treatment to Bolster the Growth of the Global Sickle Cell Disease Treatment Industry
Based on treatment, the blood transfusion segment is predicted to account for a significant market share in the sickle cell disease treatment industry. This increase can be associated with the increased accessibility of blood transfusion treatment compared to other forms of treatment. In addition, blood transfusion helps to treat anaemia and prevent stroke. Furthermore, it is used to dilute the sickled haemoglobin with normal haemoglobin in order to treat chronic pain, acute chest syndrome, splenic sequestration, and other complications. Thus, this segment is estimated to positively catalyse the market growth in the forecast period.
North America to Occupy a Substantial Market Share in the Global Sickle Cell Disease Treatment Industry
North America is expected to occupy a substantial share of the sickle cell disease treatment industry in the forecast period. This growth can be attributed to the presence of a large African-American population in the region, which is more susceptible to sickle cell disease. In addition, the rising accessibility to resources and treatment facilities with increased disposable income and highly advanced healthcare infrastructure are also contributing to the growth. Meanwhile, in the African region, in countries such as Cameroon, the Republic of Congo, Gabon, Ghana, and Nigeria, the prevalence of sickle cell disease is between 20% and 30%. At the same time, it is as high as 45% in some parts of Uganda, as stated by the WHO. Moreover, in this region, the majority of children with the most severe form of the disease die prior to the age of 5, usually from an infection or severe blood loss. Thus, the growing awareness about sickle cell disease treatment and the improving healthcare facilities in Africa are expected to provide lucrative growth opportunities to the market.
Sickle Cell Disease Treatment: Market Segmentation
Sickle cell disease refers to a commonly found blood disorder. This disease is inherited by the children whose parents carry either sickle cell disease or sickle cell trait. This disease leads to abnormal haemoglobin generation, which is rigid and shaped like a sickle that can get stuck and block blood flow, which causes interference with oxygen delivery. This leads to pain, infections, stroke, acute chest syndrome, organ damage, and other disabilities. In addition, the drastic complications pertaining to sickle cell disease include premature death in some cases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By treatment, the market is divided into:
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Incidences of Sickle Cell Disease to Augment the Growth of the Global Sickle Cell Disease Treatment Industry
According to the WHO statistics, an estimated 5% of the world’s population carries trait genes for haemoglobin disorders, mainly sickle-cell disease and thalassaemia. In addition, more than 300,000 babies with severe haemoglobin disorders are born each year. The countries worldwide and international organisations are strategising initiatives to control and prevent sickle cell disease risks. Moreover, with the growing geriatric population worldwide, which is more susceptible to chronic disorders, governments are increasingly investing in the healthcare sector to reduce mortality risks. As a result, sickle cell disease treatment is in huge demand for the early detection of the disease. For instance, The Kidney Cancer Association (KCA) and the Sickle Cell Disease Association of America, Inc. (SCDAA) partnered to launch a programme called KNOW & TELL to raise awareness about sickle cell trait and its potential connection with a rare type of kidney cancer known as renal medullary carcinoma (RMC). Such initiatives are expected to augment the market growth in the forecast period.
Key Industry Players in the Global Sickle Cell Disease Treatment Market
The report gives a detailed analysis of the following key players in the global sickle cell disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Emmaus Life Sciences, Inc.
- Global Blood Therapeutics, Inc.
- bluebird bio, Inc.
- Pfizer Inc.
- Novartis International AG
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Diseases Type |
|
| Breakup by Population Type |
|
| Breakup by Dosage Form |
|
| Breakup by Drug Type |
|
| Breakup by End User |
|
| Breakup by Treatment Channel |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Sickle Cell Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Sickle Cell Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Sickle Cell Epidemiology (2016-2031)
5.3 Europe Sickle Cell Epidemiology (2016-2031)
5.4 Asia-Pacific Sickle Cell Epidemiology (2016-2031)
5.5 Latin America Sickle Cell Epidemiology (2016-2031)
5.6 Middle East & Africa Sickle Cell Epidemiology (2016-2031)
6 Global Sickle Cell Disease Treatment Market Overview
6.1 Global Sickle Cell Disease Treatment Market Historical Value (2017-2023)
6.2 Global Sickle Cell Disease Treatment Market Forecast Value (2024-2032)
7 Global Sickle Cell Disease Treatment Market Landscape
7.1 Global Sickle Cell Disease Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Sickle Cell Disease Treatment Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Population Type
7.2.3 Analysis by End User
8 Sickle Cell Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Sickle Cell Disease Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Sickle Cell Disease Treatment Market Segmentation
11.1 Global Sickle Cell Disease Treatment Market by Treatment Type
11.1.1 Market Overview
11.1.2 Medications
11.1.2.1 Antibiotics
11.1.2.2 Pain-Relieving Medications
11.1.2.3 Hydroxyurea
11.1.2.4 Others
11.1.3 Blood Transfusion
11.1.4 Bone Marrow Transplant
11.1.5 Others
11.2 Global Sickle Cell Disease Treatment Market by Diseases Type
11.2.1 Market Overview
11.2.2 Hemoglobin Sβ0 Thalassemia
11.2.3 Hemoglobin Sβ+ Thalassemia
11.2.4 Hemoglobin SC
11.2.5 Others
11.3 Global Sickle Cell Disease Treatment Market by Population Type
11.3.1 Market Overview
11.3.2 Pediatrics
11.3.3 Adults
11.4 Global Sickle Cell Disease Treatment Market by Dosage Form
11.4.1 Market Overview
11.4.2 Tablet
11.4.3 Capsule
11.4.4 Parentals
11.4.5 Others
11.5 Global Sickle Cell Disease Treatment Market by Drug Type
11.5.1 Market Overview
11.5.2 Over the Counter
11.5.2.1 Generics
11.5.2.2 Branded
11.5.3 Prescription
11.6 Global Sickle Cell Disease Treatment Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Specialty Clinics
11.6.4 Homecare
11.6.5 Others
11.7 Global Sickle Cell Disease Treatment Market by Treatment Channel
11.7.1 Market Overview
11.7.2 Public
11.7.3 Private
11.8 Global Sickle Cell Disease Treatment Market by Distribution Channel
11.8.1 Market Overview
11.8.2 Hospital Pharmacy
11.8.3 Online Pharmacy
11.8.4 Retail Pharmacy
11.9 Global Sickle Cell Disease Treatment Market by Region
11.9.1 Market Overview
11.9.2 North America
11.9.3 Europe
11.9.4 Asia Pacific
11.9.5 Latin America
11.9.6 Middle East and Africa
12 North America Sickle Cell Disease Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Sickle Cell Disease Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Sickle Cell Disease Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Sickle Cell Disease Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Sickle Cell Disease Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Bluebird bio, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Bristol-Myers Squibb Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Endo Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Teva Pharmaceutical Industries Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Mayne Pharma Group Limited
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 CELGENE CORPORATION
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ironwood Pharmaceuticals, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Amgen Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Zydus Cadila
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Silver Lake Research Corporation
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Ionis Pharmaceuticals, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Vertex Pharmaceuticals Incorporated
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
24 Sickle Cell Disease Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The sickle cell disease treatment market reached a value of USD 5.38 billion in 2023.
The market is projected to expand at a CAGR of 16.9% from 2024 to 2032, growing to USD 21.92 billion by 2032.
The major drivers of the industry include rising accessibility to resources and treatment facilities, increased disposable income, highly advanced healthcare infrastructure, growing awareness about sickle cell disease treatment, and increasing demand for blood transfusion treatment.
The key market trends guiding the growth of the industry include the increasing investments in the healthcare sector and growing geriatric population worldwide.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant segments based on treatment include blood transfusion, pharmacotherapy, and bone marrow transplant.
The major players in the industry are Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer Inc., and Novartis International AG, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER